Siddappa Byrareddy, PhD

Professor, Vice-Chair of ResearchSid Byrareddy

Durham Research Center 8052
58800 Nebraska Medical Center
Omaha, NE  68198-5880

Phone: 402-559-5416
E-mail: Sid Byrareddy, PhD

Keywords: HIV/SIV/SHIV, neuroAIDS, transmission, drugs of abuse, HIV cure, gut homing molecules, immunotherapy, mucositis, Zika virus, SARS-CoV-2, COVID-19, Monkeypox 2022

In the news
Research summary
Ongoing and future research projects
Representative publications
Dr. Byrareddy's biographical information
Visit Dr. Byrareddy's laboratory

Currently recruiting graduate students. Please contact if you are interested. 

Research Technologist position available. Visit Opportunities page.

In the news

NSRI | July 7, 2022
Phenotypic & functional characterization of newly evolved SARS-CoV-2 mutant viruses

UNMC Today | June 9, 2022
UNMC sees continued success in ultra-long acting HIV medicines

UNMC Today | December 30, 2021
Dr. Byrareddy's lab explores omicron

UNMC Today | November 24, 2021
Research highlights

UNMC Today | November 1, 2021
UNMC team helps ID antivirals to use against COVID-19

UNMC Today | September 23, 2021
Article sheds light on pandemic's impact on mental health

UNMC Today | August 20, 2021
Paper by Dr. Byraraddy's lab explores variants of SARS-CoV-2 viruses

UNMC Today | August 19, 2021
NSRI awards $50,000 to UNMC researchers

UNMC Today | July 13, 2021
COVID-19 analysis looks at variant spread

UNMC Today | May 26, 2021
Research highlights

BioSpectrum | March 22, 2021
IISER Bhopal, Nebraska University suggest repurposing Rapamycin to treat COVID-19

UNMC Today | January 27, 2021
COVID-19 paper is UNMC's most-cited of 2020

National Institute on Drugs of Abuse | December 23, 2020
Substance Use Status Important When Developing HIV Therapies

UNMC Today | November, 13 2020
Research highlights

Forbes | July 6, 2020
Cannabis may reduce deadly COVID-19 lung inflammation, researchers explain why

Business Insider | May 10, 2020
As the coronavirus case curve flattens, daily deaths may stay high, experts warn

View comments from other journals, universities and news organizations.

Research summary

Our laboratory focuses on understanding host-virus dynamics using molecular biology, virology, immunology, systems biology, and genomic tools to develop prevention strategies for HIV/AIDS and other infectious diseases such as SARS-CoV-2 and Zika virus. We use non-human primate models most often for in vivo studies, while also using small animal models. Our long-term goal is to set up well-controlled clinical cohorts in tandem for testing the disease outcomes in relevant animal models as a synergistic platform for preclinical development of vaccines/therapeutics.

Ongoing and future research interests

  1. Dynamics of host-virus interaction and development of biologically relevant primate models. Our research is focused on the generation of biologically relevant primate models using Transmitter/Founder viruses (T/F) env.  We mostly focus on developing a non-human primate model to study HIV associated neurocognitive disorders (HAND) in relevant animal model in the era of cART. Furthermore, predominant route of HIV-1 infection occurs following sexual contact with vaginal transmission accounting for the majority of all newly acquired infections worldwide. Knowledge on how HIV disseminates within the genital mucosa following initial introduction and subsequent gradual spread to the lymphoid compartments as well as CNS is still elusive. We will address these questions systematically using biologically relevant primate models.
  2. To understand the role of Env Glycosylation in mucosal transmission/host virus interaction. Viral env glycosylation is thought to influence preferential transmission by selecting receptors for cellular entry and rendering its susceptibility to neutralizing antibodies. Our laboratory evaluates the role of env glycans using a set of HIV-1 clade C molecular clones predominantly obtained from transmitted/founder (T/F) viruses of a Zambian cohort. The overall goal of this research is to provide improved understanding of virus-host relationships that promote transmission and contribute to the rate of disease progression following infection, which are in turn critical for effective HIV vaccine design.
  3. Functional Cure of HIV. We are developing strategies aimed at limiting inflammation and improving immune responses in the gut as well as other lymphoid tissues. Our ultimate goal is to develop combinatorial therapeutic intervention strategies for antiretroviral therapy treatment.
  4. Mechanistic studies of NeuroAIDS/Drugs of abuse. We are using the SIV/macaque models to evaluate the brain as a viral reservoir in the setting of antiretroviral treatment. Although most reservoir work has concentrated mostly on CD4+ T cells, these are not the primary infected cells in the CNS, where long-lived macrophages and microglia take this role instead. Furthermore, drugs of abuse are frequently co-morbid with HIV-1 infection and further affects the CNS. We are studying the effects of drugs of abuse/immunotherapy on modulating the effectiveness of antiretroviral treatment by monitoring changes in cellular/immunological markers possibly impacting infection and tissue migration both in brain cells as well as in lymphoid cells.
  5. Zika Virus host-virus interactions. The Zika virus (ZIKV) is a newly emerging pathogen that has resulted in a worldwide epidemic. Our laboratory began working on this virus in late 2016 and developed several leads in order to understand the virus pathogenesis and development of therapeutics. We have demonstrated that intersecting polyamine catabolism pathways with polyamine analogues derivatives can inhibit ZIKV replication. As a result, we are currently investigating polyamine analogues as potential treatment to Zika. We also developed a macaque model for Zika infection in order to understand virus immune cell dynamics, glycosylation, and co-infection with other viruses, such as HIV, dengue virus.

top of page

Representative publications

  1. Abdelmoaty MM, Yeapuri P, Machhi J, Olson KE, Shahjin F, Kumar V, Zhou Y, Liang J, Pandey K, Acharya A, Byrareddy SN, Mosley RL, Gendelman HE. Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions. Front Immunol. 2021 Oct 4;12:741502. doi: 10.3389/fimmu.2021.741502. PMID: 34671355; PMCID: PMC8521106.
  2. Johnson SD, Fox HS, Buch S, Byrareddy SN. Chronic Opioid Administration is Associated with Prevotella-dominated Dysbiosis in SIVmac251 Infected, cART-treated Macaques. J Neuroimmune Pharmacol. 2021 Mar 31. doi: 10.1007/s11481-021-09993-4. Epub ahead of print. PMID: 33788119.

  3. Fletcher CV, Dyavar SR, Acharya A, Byrareddy SN. The Contributions of Clinical Pharmacology to HIV Cure Research. Clin Pharmacol Ther. 2021 Mar 24. doi: 10.1002/cpt.2237. Epub ahead of print. PMID: 33763860.

  4. Acharya A, Olwenyi OA, Thurman M, Pandey K, Morsey BM, Lamberty B, Ferguson N, Callen S, Fang Q, Buch SJ, Fox HS, Byrareddy SN. Chronic morphine administration differentially modulates viral reservoirs in SIVmac251 infected rhesus macaque model. J Virol. 2020 Dec 16:JVI.01657-20. doi: 10.1128/JVI.01657-20. Epub ahead of print. PMID: 33328304. PMCID: PMC8092838.

  5. McGuinty M, Angel JB, Cooper CL, Cowan J, MacPherson PA, Kumar A, Murthy S, Sy R, Dennehy M, Tremblay N, Byrareddy SN, Cameron DW. Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. BMJ Open. 2020;10(10):e041359. Published 2020 Oct 8. doi:10.1136/bmjopen-2020-041359

  6. Pino M, Uppada SB, Pandey K, King C, Nguyen K, Shim I, Rogers K, Villinger F, Paiardini M, Byrareddy SN. Safety and Immunological Evaluation of Interleukin-21 Plus Anti-α4β7 mAb Combination Therapy in Rhesus Macaques. Front Immunol. 2020 Jul 17;11:1275. doi: 10.3389/fimmu.2020.01275. PMID: 32765488; PMCID: PMC7379916.

  7. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26. PMID: 32113704; PMCID: PMC7127067.

  8. Dave RS, Ali H, Sil S, Knight LA, Pandey K, Madduri LSV, Qiu F, Ranga U, Buch S, Byrareddy SN. NF-κB Duplications in the Promoter-Variant HIV-1C LTR Impact Inflammation Without Altering Viral Replication in the Context of Simian Human Immunodeficiency Viruses and Opioid-Exposure. Front Immunol. 2020 Jan 31;11:95. doi: 10.3389/fimmu.2020.00095. PMID: 32076422; PMCID: PMC7006833.

  9. Namasivayam V, Vanangamudi M, Kramer VG, Kurup S, Zhan P, Liu X, Kongsted J, Byrareddy SN. The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. J Med Chem. 2019 May 23;62(10):4851-4883. doi: 10.1021/acs.jmedchem.8b00843. Epub 2018 Dec 27. PMID: 30516990; PMCID: PMC7049092.

  10. Santangelo PJ, Cicala C, Byrareddy SN, Ortiz KT, Little D, Lindsay KE, Gumber S, Hong JJ, Jelicic K, Rogers KA, Zurla C, Villinger F, Ansari AA, Fauci AS, Arthos J. Early treatment of SIV+ macaques with an α4β7mAb alters virus distribution and preserves CD4+ T cells in later stages of infection. Mucosal Immunol. 2018 May;11(3):932-946. doi: 10.1038/mi.2017.112. Epub 2017 Dec 20. PMID: 29346349; PMCID: PMC5976508.

  11. Santangelo PJ, Rogers KA, Zurla C, Blanchard EL, Gumber S, Strait K, Connor-Stroud F, Schuster DM, Amancha PK, Hong JJ, Byrareddy SN, Hoxie JA, Vidakovic B, Ansari AA, Hunter E, Villinger F. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat Methods. 2015 May;12(5):427-32. doi: 10.1038/nmeth.3320. Epub 2015 Mar 9. PMID: 25751144; PMCID: PMC4425449.

  12. Byrareddy SN, Kallam B, Arthos J, Cicala C, Nawaz F, Hiatt J, Kersh EN, McNicholl JM, Hanson D, Reimann KA, Brameier M, Walter L, Rogers K, Mayne AE, Dunbar P, Villinger T, Little D, Parslow TG, Santangelo PJ, Villinger F, Fauci AS, Ansari AA. Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat Med. 2014 Dec;20(12):1397-400. doi: 10.1038/nm.3715. Epub 2014 Nov 24. PMID: 25419708; PMCID: PMC4257865.

  13. Takahashi Y, Byrareddy SN, Albrecht C, Brameier M, Walter L, Mayne AE, Dunbar P, Russo R, Little DM, Villinger T, Khowawisetsut L, Pattanapanyasat K, Villinger F, Ansari AA. In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection. PLoS Pathog. 2014 Mar 6;10(3):e1003929. doi: 10.1371/journal.ppat.1003929. PMID: 24603870; PMCID: PMC3946395.

  14. Dutta D, Johnson S, Dalal A, Deymier MJ, Hunter E, Byrareddy SN. High throughput generation and characterization of replication-competent clade C transmitter-founder simian human immunodeficiency viruses. PLoS One. 2018 May 14;13(5):e0196942. doi: 10.1371/journal.pone.0196942. PMID: 29758076; PMCID: PMC5951672.

More publications in PubMed

Dr. Byrareddy's biographical information
Visit Dr. Byrareddy's laboratory
Dr. Byrareddy’s COVID-19 research
top of page